Navigation Links
Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172
Date:8/14/2008

e (aPTT). The highest infusion dose rate tested, 6.0 mg/kg/hr, resulted in an average ACT per subject ranging from 373 to 414 seconds and an increase of approximately three times baseline. Average PT values per subject ranged from 56 to 92 seconds and had an increase of approximately five times baseline. Average aPTT values per subject ranged from 130 to 178 seconds and had an increase of approximately five times baseline. All measurements were maintained stably throughout the four-hour infusion. Once the infusion ended, the ACT and other coagulation parameters showed a rapid return toward baseline, consistent with the short plasma half-life of NU172 observed in the Phase 1a trial. In addition, NU172 was well-tolerated with no serious adverse events.

"In this study, we were able to identify a dose that meets or exceeds the level of anticoagulation needed for the indications we plan to evaluate, including CABG surgery," said Dr. Ted W. Love, chairman and chief executive officer of Nuvelo. "In addition to supporting our previous proof-of-concept data, the Phase 1b study shows that anticoagulation with NU172 can be maintained for four hours, which is longer than a typical CABG procedure. We are on track to launch a Phase 2 study evaluating NU172 in the fourth quarter of 2008 or the first quarter of 2009."

Approximately 450,000 CABG procedures, 50 million dialysis procedures, and 1.2 million PCIs are performed annually in the U.S. During these procedures, anticoagulants are given to prevent blood clotting. In CABG procedures and often in dialysis, the anticoagulation effect of heparin must be reversed with protamine once the procedure has been completed.

About Aptamers and NU172

Aptamers are chemically synthesized single-stranded nucleic acids that form well-defined three-dimensional shapes, allowing them to bind target molecules in a manner that is conceptually similar to antibodies. Characteristics of aptamers include high specificity and a
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
2. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
3. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
4. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
5. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
6. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
7. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. NewCardio Announces Positive Results From Third Clinical Validation Study
10. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
11. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... to Fix the Bill ,, WASHINGTON, Dec. ... Coalition for a Competitive Pharmaceutical Market (CCPM) will ... and in select states charging that, during this ... gift of all to brand pharmaceutical companies" by ... ads urge the President to tell Congress to ...
(Date:12/17/2009)... PALM CITY, Fla., Dec, 17 Connectyx ... today that it has formed a distribution partnership ... Order distributor of Diabetic Supplies, Respiratory Supplies and ... the VED Erectile Dysfunction System. ,, Terms of ... Ronn Schuman stated that, "This partnership adds to ...
(Date:12/17/2009)... Dec. 17 Frost & Sullivan ... American Healthcare Innovation Award in molecular diagnostics ... its commitment to providing innovative technologies for ... its incorporation in 2004, IntelligentMDx has introduced ... to make tests that are clinically impactful, ...
Breaking Medicine Technology:Coalition for a Competitive Pharmaceutical Market Runs Ads Stating Congress Is Giving 'Greatest Holiday Gift of All to Brand Pharmaceutical Companies' 2Coalition for a Competitive Pharmaceutical Market Runs Ads Stating Congress Is Giving 'Greatest Holiday Gift of All to Brand Pharmaceutical Companies' 3Connectyx Announces Distribution Partnership with United States Medical Supply 2Connectyx Announces Distribution Partnership with United States Medical Supply 3Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 2Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 3Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 4Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 5Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading 3A Studies Actually Show it is Effective at Reducing Pain 53944 1Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading 3A Studies Actually Show it is Effective at Reducing Pain 53944 2Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading 3A Studies Actually Show it is Effective at Reducing Pain 53944 3Hospice Partners On Call Selects Category 5 Hurricane Rated 1Vault Networks to Safeguard Server and Call Center Infrastructure 53942 1Hospice Partners On Call Selects Category 5 Hurricane Rated 1Vault Networks to Safeguard Server and Call Center Infrastructure 53942 2FDA Approves New 3000 IU Vial Size for Kogenate 28R 29 FS antihemophilic factor 28recombinant 29 53939 1FDA Approves New 3000 IU Vial Size for Kogenate 28R 29 FS antihemophilic factor 28recombinant 29 53939 2FDA Approves New 3000 IU Vial Size for Kogenate 28R 29 FS antihemophilic factor 28recombinant 29 53939 3FDA Approves New 3000 IU Vial Size for Kogenate 28R 29 FS antihemophilic factor 28recombinant 29 53939 4
(Date:12/17/2009)... 17 On the heels of unveiling the ... the 2010 race, LA Marathon officials today announced a ... raising funds for causes ranging from cancer research to ... expanded charity program is in line with the vision ... has the potential to be a huge philanthropic force ...
(Date:12/17/2009)... /PRNewswire-Asia/ -- China,s leading high-tech,healthcare group, Golden Meditech ... 801) is pleased to announce today the interim ... review, the Group,s two,associate companies made their debut ... key businesses have been strengthened, with maiden revenue ... , Mr. KAM Yuen, ...
(Date:12/17/2009)... Jay and Maureen Neitz, the husband-and-wife team whose pioneering ... to treat vision disorders, as the inaugural recipients of ... The award is funded by a $1 million endowment ... Jay Pepose ,75 and Susan K. Feigenbaum ,74, his ... vision science. , The Neitzes, both of whom are ...
(Date:12/17/2009)... need to monitor cell phone use in era of ... 17 (HealthDay News) -- Teens and preteens spend hours ... content of some of those messages -- sexually explicit ... causing growing concern among parents, University of Michigan researchers ... that 41 percent of parents are worried about the ...
(Date:12/17/2009)... firm’s Interim Leadership division as senior vice president. A seasoned executive ... assume her duties at B. E. Smith today. , ... ... Smith recently hired Deirdre Byrne to lead the firm’s Interim ... 20 years of experience in healthcare consulting, Byrne will assume her ...
Breaking Medicine News(10 mins):Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 2Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 3Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 4Health News:Golden Meditech Announces Interim Results of FY2009/10 2Health News:Golden Meditech Announces Interim Results of FY2009/10 3Health News:Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis 2Health News:'Sexting' by Kids Begets Fretting by Parents 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 3
... technique allowing doctors to operate on patients by ... potentially replace certain types of conventional surgery in ... have successfully demonstrated the procedure in pigs. , ... trials, researchers say it could circumvent the long ...
... Kate Weber, registered dietician, certified personal trainer, marathoner, and wellness enthusiast ... to live a better, longer, healthier and younger ... ... Dec. 17 be, better nutrition for active,lifestyles available exclusively at ...
... ... Procedures, CLEVELAND, Dec. ... Software, announced today that,it has donated over $71,000 in software to ... improve lives,worldwide through research, education, and services in family health. FHI,will ...
... at UCLA and NanoPacific Holdings Inc. have announced a ... lead to prolonged lives of enhanced quality for millions ... terms of the partnership, NanoPacific will receive exclusive license ... at the CNSI,s Nano Machine Center. The newly formed ...
... 17 ULURU Inc. (Amex:,ULU) today announced that ... the,United States Patent and Trademark Office for its ... science behind the Company,s,nanoparticle aggregate technology; consequently, this ... Commenting on the issuance of the Notice ...
... CSG/SportsCoatings,today announced a major deal that brings ... to 25 high schools in,Virginia,s Fairfax County ... is the model for how schools and ... minimizing prevalent,bacterial issues like staph and MRSA," ...
Other Medicine News:Health News:Z-shaped incision enhances minimally invasive surgery 2Health News:Z-shaped incision enhances minimally invasive surgery 3Health News:be(R) is Making Health Simple With Complimentary, Expert Online Diet, Nutrition and Exercise Advice 2Health News:IQS Donates Quality Management Software to Family Health International 2Health News:IQS Donates Quality Management Software to Family Health International 3Health News:UCLA-industry partnership to develop, commercialize new nanotechnology 2Health News:UCLA-industry partnership to develop, commercialize new nanotechnology 3Health News:ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent 2Health News:Virginia School District Gets Proactive Against MRSA 2
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
... Inverness Medical Professional Diagnostics is a ... extensive IFA and DFA test menu that ... and STDs as well as miscellaneous conjugates ... give you a wide assortment of substrates ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
Medicine Products: